SOX10在三阴性基底样型乳腺癌诊断中的临床价值

Clinical value of SOX10 in diagnosis of Triple negative basal-like breast cancer

目的探讨SOX10在三阴性基底样型乳腺癌诊断中的潜在临床应用价值。方法选取2019年1月~2019年12月在重庆医科大学附属第一医院病理科首次确诊为乳腺癌的患者组织样本171例,按照免疫组化分子分型,分为三阴性基底样型、三阴性非基底样型、LuminalA型、Luminal B HER2阴性型、Luminal B HER2阳性型、HER2阳性型,对所有样本进行SOX10免疫组化检测,分析SOX10的表达与分子分型的相关性。用受试者工作特征曲线(ROC)评估该指标的特异性及敏感性。结果SOX10在三阴性基底样型、三阴性非基底样型、LuminalA型、Luminal B HER2阴性型、Luminal B HER2阳性型、HER2阳性型中的阳性率分别为80.9%(38/47)、42.9%(3/7)、0.0%(0/28)、0.0%(0/44)、0.0%(0/17)、3.6%(1/28)。与其它分子分型相比,三阴性基底样型乳腺癌中SOX10表达明显升高(P<0.005)。SOX10作为标志物诊断三阴性基底样型乳腺癌的ROC曲线下面积为0.888。结论SOX10在三阴性基底样型乳腺癌中特异性高表达,可能成为该疾病的诊断指标和潜在治疗靶点。

Objective To investigate the potential clinical value of SOX10 in diagnosis of Triple negative basal-like breast cancer.Methods A total of 171 tissue samples of breast cancer were collected from Department of Pathology,The First Affiliated Hospital of Chongqing Medical University from January 2019 to December 2019.All patients were divided into Triple negative basal-like type,Triple negative non-basal-like type,Luminal A type,Luminal B HER2 negative type,Luminal B HER2 positive type and HER2 positive type according to immunohistochemical results.All samples were tested for SOX10 immunohistochemistry.The correlation between SOX10 expression and molecular subtypes was performed.The specificity and sensitivity of SOX10 were evaluated by receiver operating characteristic curve(ROC).Results The expressions rate of SOX10 inTriple negative basal-like type,Triple negative non-basal-like type,Luminal A type,Luminal B HER2 negative type,Luminal B HER2 positive type and HER2 positive type were 80.9%(38/47),42.9%(3/7),0.0%(0/28),0.0%(0/44),0.0%(0/17),3.7%(1/28),respectively.SOX10 expression was significantly increased in Triple negative basal-like breast cancer compared with other molecular subtypes(80.9%vs.3.2%,P<0.005).The area under the ROC curve of SOX10 for the diagnosis of Triple negative basal-like breast cancer was 0.888.Conclusion SOX10 was expressed highly and specifically in Triple negative basal-like breast cancer,which may be a diagnostic indicator and potential therapeutic target of this disease.